Dosing and Administration Guide for ARZERRA
|
|
- Cynthia Brittney George
- 5 years ago
- Views:
Transcription
1 Dosing and Administration Guide for ARZERRA INDICATIONS for ARZERRA (ofatumumab) In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL For the treatment of patients with CLL refractory to fludarabine and alemtuzumab IMPORTANT SAFETY INFORMATION for ARZERRA (ofatumumab) WARNING: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY Hepatitis B Virus (HBV) reactivation can occur in patients receiving CD20-directed cytolytic antibodies, including ARZERRA, in some cases resulting in fulminant hepatitis, hepatic failure, and death Progressive Multifocal Leukoencephalopathy (PML) resulting in death can occur in patients receiving CD20-directed cytolytic antibodies, including ARZERRA Please see additional Important Safety Information on pages To learn more, please visit products/arzerra.
2 Welcome Understanding the Difference Between First-Line, Extended Treatment Following Two or More Lines of Therapy, and FA-Refractory Dosing for ARZERRA This guide is designed to be used as a quick reference for the proper dosing of ARZERRA in the treatment of first-line CLL, extended treatment following two or more lines of therapy, and CLL that is refractory to fludarabine and alemtuzumab (FA). For your convenience, dosing instructions specific to each indication are organized separately: first-line CLL in the first section (page 4), extended treatment after at least two lines of therapy in the second section (page 8), and FA-refractory CLL in the third section (page 12). General information about product handling is covered in the fourth section (page 18). If you have any questions regarding ARZERRA or would like to schedule an in-service program, please contact Novartis Pharmaceuticals Corporation or visit us at Table of Contents Dosing for ARZERRA Plus Chlorambucil for First-Line CLL...4 Dosing Recommendations... 4 Premedication... 5 Infusion Rates... 6 Dosing for ARZERRA for Extended Treatment of Patients With CLL After at Least Two Lines of Therapy Dosing Recommendations... 8 Premedication... 9 Infusion Rates Dosing for ARZERRA for CLL Refractory to Fludarabine and Alemtuzumab...12 Dosing Recommendations Premedication Infusion Rates Infusion Rate Dose Modifications for Infusion Reactions Product Handling...18 Preparation of Solution Administration How Supplied Storage Support and Resources Indications and Important Safety Information
3 Dosing for ARZERRA Plus Chlorambucil for First-Line CLL 1 Dosing for ARZERRA Treatment should be continued for a minimum of 3 cycles until best response* or a maximum of 12 cycles Cycle mg Day 1 Day mg Cycles 2 up to 12 Day 1 of each 28-day cycle 1000 mg Median infusion time: 5.2 hours for Cycle 1, Day 1 Chlorambucil: and 4.2 to 4.4 hours for subsequent infusions 10 mg/m 2 orally days 1-7 of each 28-day cycle 1 Please note: The chlorambucil dosing information seen here was evaluated in the pivotal trial, but is not a recommendation from the Dosage and Administration section of the Prescribing Information 2 In the pivotal trial 1 : Cycle 1 Cycles 2 through 6 Median number of cycles completed was 6 Dosing Recommendations 1 Day mg Day mg Day 1 of each 28-day cycle 1000 mg Administer ARZERRA in an environment where facilities to adequately monitor and treat infusion Median infusion time: 5.3 hours for Cycle 1, Day 1 reactions and are 4.1 to available 4.2 hours for subsequent infusions Prepare according to instructions on page 18 Administer as an intravenous (IV) infusion according to the schedule outlined above Do not administer as an IV push or bolus or as a subcutaneous injection Weekly Every 4 Weeks Premedicate before each infusion Weeks 1-8 Dose 1 4 Weeks 12, 16, 20, 24 * The pivotal trial defined best response as 2 consecutive response assessments of stable disease, partial response, or complete response. 1 Please 300 mgsee Doses Important 2000 mgsafety Doses Information 2000 mg on pages Administer first and second infusions over 6.5 hours; Premedication 1 Patients should receive all of the following premedication agents 30 minutes to 2 hours prior to each infusion of ARZERRA Oral acetaminophen 1000 mg (or equivalent) plus Oral or IV antihistamine (diphenhydramine 50 mg or cetirizine 10 mg or equivalent) plus IV corticosteroid (prednisolone 50 mg or equivalent) Corticosteroid may be reduced or omitted for subsequent infusions if a grade 3 or greater infusion-related adverse event did not occur during the first 2 infusions Infusion reactions may occur despite premedication After Cycle 1, ARZERRA is dosed in 28-day cycles. IMPORTANT SAFETY INFORMATION Infusion Reactions ARZERRA can cause serious, including fatal, infusion reactions manifesting as bronchospasm, dyspnea, laryngeal edema, pulmonary edema, flushing, hypertension, hypotension, syncope, cardiac events, back pain, abdominal pain, pyrexia, rash, urticaria, angioedema, cytokine release syndrome, and anaphylactoid/anaphylactic reactions. 5 First-Line CLL Dosing
4 Dosing for ARZERRA Plus Chlorambucil for First-Line CLL 1 Infusion Rates Infusion initiation rates for ARZERRA Dose Initial 300-mg dose Subsequent infusions of 1000 mg Infusion Initiation Rates mg/hour ml/hour Initiate infusion at a rate of 12 mg/hour if a grade 3 or greater infusion-related adverse event was experienced during the previous infusion In the absence of an infusion-related adverse event, the rate of infusion may be increased every 30 minutes as described in the Infusion Rate Table to the right. Do not exceed the infusion rates in the following Infusion Rate Table Infusion Reactions (cont d) Administer ARZERRA in an environment where facilities to adequately monitor and treat infusion reactions are available. Premedicate with acetaminophen, an antihistamine, and a corticosteroid. Infusion reactions may occur despite premedication. Interrupt ARZERRA for infusion reactions of any severity and initiate appropriate medical treatment. If an anaphylactic reaction occurs, immediately and permanently discontinue ARZERRA. Infusion rates for ARZERRA Interval After Start of Infusion (min) Initial 300-mg Dose a (ml/hour) Subsequent Infusions b (ml/hour) > a Initial 300 mg: Median durations of infusions=4.8 to 5.2 hours. b Subsequent infusions of 1000 mg: Median durations of infusions=4.2 to 4.4 hours. Hepatitis B Virus (HBV) Reactivation HBV reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, has occurred in patients treated with ARZERRA. Screen all patients for HBV infection before initiating ARZERRA. Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following treatment with ARZERRA. HBV reactivation has been reported for at least 12 months following completion of therapy. In ARZERRA-treated patients who develop reactivation of HBV, immediately discontinue ARZERRA and any concomitant chemotherapy, and institute appropriate treatment. 6 7
5 Dosing for ARZERRA for Extended Treatment of Patients With CLL After at Least Two Lines of Therapy 1 What Is Extended Treatment? Patients who achieve a partial or complete response to therapy may continue to have a leukemic burden, which could lead to progression. At the time of the efficacy analysis in the clinical trial, the median follow-up was 19.4 months with the ARZERRA arm and 18.7 months with the observation arm. The event rate (progressed or died) was 33% in the ARZERRA arm and 51% in the observation arm. Dosing for ARZERRA Single-agent ARZERRA for a maximum of 2 years Cycle mg Day 1 Day mg 7 Weeks Later and Every 8 Weeks 1000 mg Dosing Recommendations 1 Administer ARZERRA in an environment where facilities to adequately monitor and treat infusion reactions are available Prepare according to instructions on page 18 Administer as an IV infusion according to the schedule outlined above Do not administer as an IV push or bolus or as a subcutaneous injection Premedicate before each infusion HBV Infection Fatal infection due to hepatitis B in patients who have not been previously infected has been observed with ARZERRA. Monitor patients for clinical and laboratory signs of hepatitis. Premedication 1 Patients should receive all of the following premedication agents 30 minutes to 2 hours prior to each infusion of ARZERRA Oral acetaminophen 1000 mg (or equivalent) plus Oral or IV antihistamine (diphenhydramine 50 mg or cetirizine 10 mg or equivalent) plus IV corticosteroid (prednisolone 50 mg or equivalent) Corticosteroid may be reduced or omitted for subsequent infusions if a grade 3 or greater infusion-related adverse event did not occur during the first 2 infusions Infusion reactions may occur despite premedication Progressive Multifocal Leukoencephalopathy (PML) PML resulting in death has occurred with ARZERRA. Consider PML in any patient with new onset of or changes in pre-existing neurological signs or symptoms. If PML is suspected, discontinue ARZERRA and initiate evaluation for PML, including neurology consultation. Extended CLL Treatment Dosing 8 9
6 Dosing for ARZERRA for Extended Treatment of Patients With CLL After at Least Two Lines of Therapy 1 Infusion Rates Infusion initiation rates for ARZERRA Dose Initial 300-mg dose Subsequent infusions of 1000 mg Infusion Initiation Rates mg/hour ml/hour Initiate infusion at a rate of 12 mg/hour if a grade 3 or greater infusion-related adverse event was experienced during the previous infusion In the absence of an infusion-related adverse event, the rate of infusion may be increased every 30 minutes as described in the Infusion Rate Table to the right. Do not exceed the infusion rates in the following Infusion Rate Table Infusion rates for ARZERRA Interval After Start of Infusion (min) Initial 300-mg Dose a (ml/hour) Subsequent Infusions b (ml/hour) > a Initial 300 mg: Median durations of infusions=4.8 to 5.2 hours. b Subsequent infusions of 1000 mg: Median durations of infusions=4.2 to 4.4 hours. Tumor Lysis Syndrome (TLS) TLS, including the need for hospitalization, has occurred in patients treated with ARZERRA. Patients with high tumor burden and/or high circulating lymphocyte counts (>25 x 10 9 /L) are at greater risk. Consider TLS prophylaxis with anti-hyperuricemics and hydration prior to infusion of ARZERRA. For treatment of TLS, administer aggressive intravenous hydration and anti-hyperuricemic agents, correct electrolyte abnormalities, and monitor renal function. Cytopenias Severe cytopenias, including neutropenia, thrombocytopenia, and anemia, can occur with ARZERRA. Pancytopenia, agranulocytosis, and fatal neutropenic sepsis have occurred in patients who received ARZERRA in combination with chlorambucil. Grade 3 or 4 late-onset neutropenia and/or prolonged neutropenia were reported in ARZERRA-treated patients. Monitor complete blood counts at regular intervals during and after conclusion of therapy, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias
7 Day mg Day mg Day 1 of each 28-day cycle Dosing for ARZERRA 1000 for mg CLL Refractory to Fludarabine and Alemtuzumab 1 Median infusion time: 5.3 hours for Cycle 1, Day 1 and 4.1 to 4.2 hours for subsequent infusions Dosing for ARZERRA ARZERRA is administered as 12 infusions over a 24-week period Weekly Every 4 Weeks Premedication Patients should receive all of the following premedication agents 30 minutes to 2 hours prior to each infusion of ARZERRA Weeks 1-8 Weeks 12, 16, 20, 24 Oral Acetaminophen Oral or IV Antihistamine IV Corticosteroid Dose mg Doses mg Doses mg Administer first and second infusions over 6.5 hours; administer subsequent infusions (3-12) over 4 hours Dosing Recommendations Administer ARZERRA in an environment where facilities to adequately monitor and treat infusion reactions are available Prepare according to instructions on page 18 Administer as an IV infusion according to the schedule outlined above Do not administer as an IV push or bolus or as a subcutaneous injection Premedicate before each infusion Immunizations Do not administer live viral vaccines to patients who have recently received ARZERRA mg Diphenhydramine 50 mg or cetirizine 10 mg or equivalent plus Prednisolone 100 mg or equivalent a a Do not reduce corticosteroid dose for Infusions 1, 2, and 9. Corticosteroid dose may be reduced as follows: Infusions 3 through 8: Corticosteroid may be reduced or omitted with subsequent infusions if a grade 3 or greater infusion reaction did not occur with the preceding infusion(s) Infusions 10 through 12: Prednisolone may be given at reduced dose of 50 mg to 100 mg (or equivalent) if a Grade 3 or greater infusion-related adverse event did not occur with Infusion 9 Infusion reactions may occur despite premedication In a study of FA-refractory patients (study 2), 88% of patients received at least 8 infusions of ARZERRA and 54% received all 12 infusions. 13 FA-Refractory CLL Dosing
8 Dosing for ARZERRA for CLL Refractory to Fludarabine and Alemtuzumab 1 Infusion Rates Infusion initiation rates for ARZERRA Infusion rates for ARZERRA Infusion Infusion 1 (300 mg) Infusion 2 (2000 mg) Infusions 3 through 12 (2000 mg) Infusion Initiation Rates mg/hour ml/hour Interval After Start of Infusion (min) Infusions 1 and 2 a (ml/hour) Subsequent Infusions b (ml/hour) > Initiate infusion at a rate of 12 mg/hour if a grade 3 or greater infusion-related adverse event was experienced during the previous infusion In the absence of an infusion-related adverse event, the rate of infusion may be increased every 30 minutes as described in the Infusion Rate Table to the right. Do not exceed the infusion rates in the following Infusion Rate Table a Infusions 1 and 2 (300 mg and 2000 mg): Median duration of infusions=6.8 hours. b Subsequent infusions of 2000 mg: Median durations of infusions=4.2 to 4.4 hours. Most Common Adverse Reactions Previously untreated CLL:( 10%, all grades) were infusion reactions (67% for ARZERRA plus chlorambucil vs 0% for chlorambucil) and neutropenia (27% vs18%). Extended treatment therapy in CLL: Common adverse reactions ( 10%) were infusion reactions, neutropenia, and upper respiratory infection. Most Common Adverse Reactions (cont d) In the single-arm refractory CLL clinical trial, the most common adverse reactions ( 10%, all grades) were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections. The most common serious adverse reactions were infections (including pneumonia and sepsis), neutropenia, and pyrexia
9 Infusion Rate Dose Modifications for Infusion Reactions 1 Infusion Rate Dose Modifications Interrupt infusion for infusion reactions of any severity. Treatment can be resumed at the discretion of the treating physician. The following infusion rate modifications can be used as a guide If the infusion reaction resolves or remains less than or equal to grade 2, resume infusion with the following modifications according to the initial grade of the infusion reaction Grade 1 or 2: Infuse at one-half of the previous infusion rate After resuming the infusion, the infusion rate may be increased according to the Infusion Rate Tables on pages 6-7, 10-11, and based on patient tolerance Consider permanent discontinuation of ARZERRA if the severity of the infusion reaction does not resolve to less than or equal to grade 2 despite adequate clinical intervention Permanently discontinue therapy for patients who develop an anaphylactic reaction to ARZERRA Infusion Rate Dose Modifications Grade 3 or 4: Infuse at a rate of 12 ml/hour Infusion reactions occur more frequently with the first 2 infusions. Laboratory Abnormalities In the previously untreated CLL clinical trial, post-baseline hematologic laboratory abnormalities (all grades) occurring with 5% incidence in patients receiving ARZERRA plus chlorambucil, and also 2% more than patients receiving chlorambucil, were leukopenia (67% for ARZERRA plus chlorambucil vs 28% for chlorambucil), neutropenia (66% vs 56%), and lymphopenia (52% vs 20%)
10 Product Handling 1 Preparation and Administration Do not shake product Inspect parenteral drug products visually for particulate matter and discoloration prior to administration. ARZERRA should be a clear to opalescent, colorless solution. The solution should not be used if discolored or cloudy, or if foreign particulate matter is present Preparation of Solution 300-mg dose: Withdraw and discard 15 ml from a 1000-mL bag of 0.9% Sodium Chloride Injection, USP. Withdraw 5 ml from each of 3 single-use, 100-mg vials of ARZERRA and add to the bag 1000-mg dose*: Withdraw and discard 50 ml from a 1000-mL bag of 0.9% Sodium Chloride Injection, USP. Withdraw 50 ml from 1 single-use, 1000-mg vial of ARZERRA and add to the bag 2000-mg dose : Withdraw and discard 100 ml from a 1000-mL bag of 0.9% Sodium Chloride Injection, USP. Withdraw 50 ml from each of 2 single-use, 1000-mg vials of ARZERRA and add to the bag Mix diluted solution by gentle inversion Store diluted solution between 2 to 8 C (36 to 46 F) No incompatibilities between ARZERRA and polyvinylchloride or polyolefin bags and administration sets have been observed Administration Instructions Administer ARZERRA in an environment where facilities to adequately monitor and treat infusion reactions are available Do not administer as an IV push or bolus or as a subcutaneous injection Do not mix ARZERRA with, or administer as an infusion with, other medicinal products Administer using an infusion pump and an administration set Flush the IV line with 0.9% Sodium Chloride Injection, USP before and after each dose Start infusion within 12 hours of preparation Discard prepared solution after 24 hours Not actual size. Product Handling Prepare all doses in 1000 ml of 0.9% Sodium Chloride Injection, USP. *First-line and extended treatment use only. FA-refractory use only
11 Product Handling 1 How Supplied Carton 3 single-use 100-mg/5-mL vials NDC Number Vial NDC Carton of 3 vials NDC Dosing Requirements 1 carton of 3 single-use vials (total of 3 vials), are needed for each 300-mg dose ARZERRA is a sterile, clear to opalescent, colorless, preservative-free liquid concentrate (20 mg/ml) for dilution and intravenous administration provided in single-use glass vials with a rubber stopper (not made with natural rubber latex) and an aluminum overseal. Each vial contains either 100 mg of ARZERRA in 5 ml of solution or 1000 mg of ARZERRA in 50 ml of solution. 1 single-use 1000-mg/50-mL vial Vial and Carton NDC ARZERRA J-Code: J carton of 1 single-use vial (total of 1 vial) is needed for each 1000-mg dose 2 cartons of 1 single-use vial (total of 2 vials) are needed for each 2000-mg dose Storage Store the vials and diluted solution of ARZERRA refrigerated between 2 to 8 C (36 to 46 F) Do not freeze Vials should be protected from light Discard prepared solution after 24 hours ARZERRA is not considered a hazardous material, so there are no biohazard requirements. Dispose per usual hospital/clinic procedures 20 21
12 Support and Resources Novartis Pharmaceuticals Corporation is committed to providing you with direct access to the resources you and your patients need while treating CLL with ARZERRA. Contact Information NOW-NOVA ( ) Monday-Friday, 8:30 am-5:00 pm ET Customer Interaction Center Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ Customized Medical Support You can request personalized assistance from an ARZERRA Medical Sciences Liaison by contacting Novartis Pharmaceuticals Corporation directly via the contact information provided at left. Available Now! Information about ARZERRA is available for you at arzerra/ and for your patients at
13 Indications and Important Safety Information INDICATIONS for ARZERRA (ofatumumab) In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabinebased therapy is considered inappropriate For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL For the treatment of patients with CLL refractory to fludarabine and alemtuzumab IMPORTANT SAFETY INFORMATION for ARZERRA (ofatumumab) WARNING: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY Hepatitis B Virus (HBV) reactivation can occur in patients receiving CD20-directed cytolytic antibodies, including ARZERRA, in some cases resulting in fulminant hepatitis, hepatic failure, and death Progressive Multifocal Leukoencephalopathy (PML) resulting in death can occur in patients receiving CD20-directed cytolytic antibodies, including ARZERRA Infusion Reactions ARZERRA can cause serious, including fatal, infusion reactions manifesting as bronchospasm, dyspnea, laryngeal edema, pulmonary edema, flushing, hypertension, hypotension, syncope, cardiac events, back pain, abdominal pain, pyrexia, rash, urticaria, angioedema, cytokine release syndrome, and anaphylactoid/anaphylactic reactions Please see additional Important Safety Information on pages 26 and 27 and click here for full Prescribing Information, including Boxed WARNING, for ARZERRA. Infusion Reactions (cont d) Administer ARZERRA in an environment where facilities to adequately monitor and treat infusion reactions are available. Premedicate with acetaminophen, an antihistamine, and a corticosteroid. Infusion reactions may occur despite premedication Interrupt ARZERRA for infusion reactions of any severity and initiate appropriate medical treatment. If an anaphylactic reaction occurs, immediately and permanently discontinue ARZERRA Hepatitis B Virus (HBV) Reactivation HBV reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, has occurred in patients treated with ARZERRA Screen all patients for HBV infection before initiating ARZERRA Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following treatment with ARZERRA. HBV reactivation has been reported for at least 12 months following completion of therapy In ARZERRA-treated patients who develop reactivation of HBV, immediately discontinue ARZERRA and any concomitant chemotherapy, and institute appropriate treatment HBV Infection Fatal infection due to hepatitis B in patients who have not been previously infected has been observed with ARZERRA. Monitor patients for clinical and laboratory signs of hepatitis Important Safety Information
14 Indications and Important Safety Information (cont d) Progressive Multifocal Leukoencephalopathy (PML) PML resulting in death has occurred with ARZERRA. Consider PML in any patient with new onset of or changes in pre-existing neurological signs or symptoms If PML is suspected, discontinue ARZERRA and initiate evaluation for PML, including neurology consultation Tumor Lysis Syndrome (TLS) TLS, including the need for hospitalization, has occurred in patients treated with ARZERRA. Patients with high tumor burden and/or high circulating lymphocyte counts (>25 x 10 9 /L) are at greater risk Consider TLS prophylaxis with anti-hyperuricemics and hydration prior to infusion of ARZERRA For treatment of TLS, administer aggressive intravenous hydration and anti-hyperuricemic agents, correct electrolyte abnormalities, and monitor renal function Cytopenias Severe cytopenias, including neutropenia, thrombocytopenia, and anemia, can occur with ARZERRA. Pancytopenia, agranulocytosis, and fatal neutropenic sepsis have occurred in patients who received ARZERRA in combination with chlorambucil. Grade 3 or 4 late-onset neutropenia and/or prolonged neutropenia were reported in ARZERRAtreated patients Monitor complete blood counts at regular intervals during and after conclusion of therapy, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias Immunizations Do not administer live viral vaccines to patients who have recently received ARZERRA Most Common Adverse Reactions Previously untreated CLL:( 10%, all grades) were infusion reactions (67% for ARZERRA plus chlorambucil vs 0% for chlorambucil) and neutropenia (27% vs18%) Extended treatment therapy in CLL: Common adverse reactions ( 10%) were inf usion reactions, neutropenia, and upper respiratory infection In the single-arm refractory CLL clinical trial, the most common adverse reactions ( 10%, all grades) were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections. The most common serious adverse reactions were infections (including pneumonia and sepsis), neutropenia, and pyrexia Laboratory Abnormalities In the previously untreated CLL clinical trial, postbaseline hematologic laboratory abnormalities (all grades) occurring with 5% incidence in patients receiving ARZERRA plus chlorambucil, and also 2% more than patients receiving chlorambucil, were leukopenia (67% for ARZERRA plus chlorambucil vs 28% for chlorambucil), neutropenia (66% vs 56%), and lymphopenia (52% vs 20%) References: 1. ARZERRA [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; Data on file. Novartis Pharmaceuticals Corp; Please see additional Important Safety Information on pages 24 and 25 and click here for full Prescribing 26 Information, 27
15 More information available at: and click here for full Prescribing Information, including Boxed WARNING, for ARZERRA Novartis 2/16 ARZ
Dosing and Administration Guide for ARZERRA
Dosing and Administration Guide for ARZERRA Indications ARZERRA (ofatumumab) is indicated: In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic
More informationCONTRAINDICATIONS None. (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARZERRA safely and effectively. See full prescribing information for ARZERRA. ARZERRA (ofatumumab)
More informationWhat You Need to Know About ARZERRA (ofatumumab)
Starting your treatment for chronic lymphocytic leukemia (CLL) What You Need to Know About ARZERRA (ofatumumab) Approved Use ARZERRA is a prescription medication used: With a chemotherapy drug called chlorambucil
More informationGAZYVA Dosing and Administration Guide
GAZYVA Dosing and Administration Guide Indications GAZYVA is a CD20-directed cytolytic antibody and is indicated: In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at
More informationADMINISTRATION GUIDE
DOSING AND ADMINISTRATION GUIDE INDICATION LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which
More informationDOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.
DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune
More informationArzerra. Arzerra (ofatumumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.03 Subject: Arzerra Page: 1 of 5 Last Review Date: June 22, 2017 Arzerra Description Arzerra (ofatumumab)
More informationPHARMACY DOSING AND ORDERING GUIDE
PHARMACY DOSING AND ORDERING GUIDE FIRST AND ONLY APPROVED TREATMENT FOR PATIENTS WITH VOD WITH RENAL OR PULMONARY DYSFUNCTION POST HSCT VOD=veno-occlusive disease Indication Defitelio (defibrotide sodium)
More informationDOSAGE FORMS AND STRENGTHS mg/40 ml (25 mg/ml) single-dose vial. (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GAZYVA safely and effectively. See full prescribing information for GAZYVA. GAZYVA (obinutuzumab)
More informationDERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:
OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationFULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CAMPATH safely and effectively. See full prescribing information for CAMPATH. CAMPATH (alemtuzumab)
More informationBLA /S-017 BLA /S-018 SUPPLEMENT APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 BLA 125486/S-017 BLA 125486/S-018 SUPPLEMENT APPROVAL Genentech, Inc. Attention: Jerald Grace, PharmD Regulatory
More informationYONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE
YONDELIS (trabectedin) DOSING & ADMINISTRATION GUIDE INDICATION YONDELIS (trabectedin) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received
More informationLEMTRADA REMS Education Program for Healthcare Facilities
For Healthcare Facilities LEMTRADA REMS Education Program for Healthcare Facilities This Educational Piece Includes Information About: The LEMTRADA REMS Program requirements to implement in your healthcare
More informationGAZYVA for Chronic Lymphocytic Leukemia (CLL)
GAZYVA for Chronic Lymphocytic Leukemia (CLL) GAZYVA is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous
More informationGUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION
GUIDELINES FOR WEIGHT-BASED DOSING AND INFUSION Includes Example dose calculation wheel Preparation and administration information for healthcare professionals Please see enclosed full Prescribing Information,
More informationPharmacy Instructions for Preparation
MARQIBO (vincristine sulfate LIPOSOME injection) Pharmacy Instructions for Preparation Important Information for Preparation 1 The instructions for the constitution of MARQIBO are provided in each kit.
More informationPRODUCT INFORMATION 1 ABOUT THIS GUIDE DOSAGE FORM AND STRENGTH STORAGE AND HANDLING
DOSING GUIDE INDICATION ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationThe only biologic approved to treat SLE: now with multiple delivery options
The only biologic approved to treat SLE: now with multiple delivery options BENLYSTA (belimumab) Autoinjector SC Prefilled syringe IV Intravenous infusion Consider the options: visit Belimumab.com INDICATION
More informationDOSING & ADMINISTRATION FOR DARZALEX (daratumumab)
JUNE 2017 UPDATE DOSING & ADMINISTRATION FOR DARZALEX (daratumumab) Indications and mechanisms of action 1 How DARZALEX is supplied DARZALEX (daratumumab) is indicated: in combination with lenalidomide
More informationPNH ahus. Dosing and Administration. For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients
For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients PNH ahus Dosing and Administration Soliris is indicated for the treatment of patients with paroxysmal
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: September 15, 2016 Gazyva Description Gazyva (obinutuzumab)
More informationPNH ahus gmg. Dosing and Administration Guide
Injection for Intravenous Use PNH ahus gmg For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus), and generalized Myasthenia Gravis (gmg) patients Dosing and Administration
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: March 16, 2018 Gazyva Description Gazyva (obinutuzumab)
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationTo learn more, visit ISTODAX.com or speak with your local Celgene representative
DOSING GUIDE FOR NURSES AND PHARMACISTS Important facts you should know about: Dosing Dosing Modifications Administration Safety To learn more, visit ISTODAX.com or speak with your local Celgene representative
More informationAdministration Tear Pad
for WG and Administration Tear Pad The first and ONLy FDA-approved therapy for Wegener s granulomatosis (WG) AND microscopic polyangiitis () Inside: Patient Checklist and Chart Record Preparation and Administration
More informationBC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab
BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab Protocol Code Tumour Group Contact Physicians LYCLLFLUDR Lymphoma Dr.
More informationDOSING AND INFORMATION GUIDE LEAPS AHEAD
DOSING AND INFORMATION GUIDE In patients with WT RAS* mcrc 1 VECTIBIX (panitumumab) LEAPS AHEAD 5.6-month increase in median OS with FOLFOX vs FOLFOX alone 1 Spot the difference. CHOOSE VECTIBIX PRIME
More informationCONTRAINDICATIONS None (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRUXIMA safely and effectively. See full prescribing information for TRUXIMA. TRUXIMA (rituximab-abbs)
More informationBC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine
BC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine Protocol Code Tumour Group Contact Physician ULYOBBEND Lymphoma
More informationRituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description
More informationFinal Labeling Text
1.14.2.3 Final Labeling Text HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Rituxan safely and effectively. See full prescribing information for
More informationNCCP Chemotherapy Regimen. Obinutuzumab and Chlorambucil Therapy
INDICATIONS FOR USE: Obinutuzumab INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities
More informationAntiemetic protocol for rare emetogenic chemotherapy - see protocol SCNAUSEA
BCCA Protocol Summary for Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma with obinutuzumab and Chlorambucil Protocol Code Tumour Group Contact Physician
More informationObinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case
Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Available
More informationDOSING AND ORDERING GUIDE
DOSING AND ORDERING GUIDE A reference guide for dosing, ordering, and product returns, plus support services for you and your patients INDICATION EMPLICITI is indicated in combination with lenalidomide
More informationINFUSING. ORENCIA (abatacept) IV INDICATION/USAGE. Your go-to guide for preparing and administering an ORENCIA intravenous (IV) infusion
INFUSING ORENCIA (abatacept) IV Your go-to guide for preparing and administering an ORENCIA intravenous (IV) infusion INDICATION/USAGE Adult Rheumatoid Arthritis (RA): ORENCIA is indicated for reducing
More informationOcrevus. (ocrelizumab) New Product Slideshow
Ocrevus (ocrelizumab) New Product Slideshow Introduction Brand name: Ocrevus Generic name: Ocrelizumab Pharmacological class: CD20-directed cytolytic monoclonal antibody Strength and Formulation: 30mg/mL;
More informationIN A STUDY OF PATIENTS WITH GPA & MPA RITUXIMAB REGIMEN DEMONSTRATED CLINICALLY SIGNIFICANT REDUCTION OF MAJOR RELAPSE RATE VS AZA 1
FDA Approved for follow-up treatment 1 * IN A STUDY OF PATIENTS WITH GPA & MPA RITUXIMAB REGIMEN DEMONSTRATED CLINICALLY SIGNIFICANT REDUCTION OF MAJOR RELAPSE RATE VS AZA 1 Rituximab regimen=roche-manufactured,
More informationA Guide for Nurses and Pharmacists CYRAMZA DOSING AND ADMINISTRATION
A Guide for Nurses and Pharmacists CYRAMZA DOSING AND ADMINISTRATION CYRAMZA (ramucirumab), in combination with docetaxel, is indicated for the treatment of patients with metastatic non-small cell lung
More information(galsulfase) DOSING & ADMINISTRATION GUIDE
(galsulfase) DOSING & ADMINISTRATION GUIDE Indication: (galsulfase) is indicated for patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). has been shown to improve walking and stair-climbing
More informationDOSING AND ADMINISTRATION GUIDE
DOSING AND ADMINISTRATION GUIDE for ADCETRIS in classical Hodgkin lymphoma (chl) ADCETRIS is indicated for the treatment of: Previously untreated Stage III/IV chl Adult patients with previously untreated
More informationKHAPZORY (levoleucovorin) for injection, for intravenous use Initial U.S. Approval: 1952 (d,l-leucovorin)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KHAPZORY safely and effectively. See full prescribing information for KHAPZORY. KHAPZORY (levoleucovorin)
More informationRiTUXimab 375 mg/m 2 Therapy-7 day
RiTUXimab 375 mg/m 2 Therapy-7 day This regimen supercedes NCCP Regimen 00208 rituximab 375mg/m2 therapy-follicular lymphoma as of February 2019 INDICATIONS FOR USE: Regimen *Reimbursement INDICATION ICD10
More informationStep-by-step instructions for intravenous (iv) infusions for patients with:
Step-by-step instructions for intravenous (iv) infusions for patients with: Rheumatoid Arthritis (RA) Systemic Juvenile Idiopathic Arthritis (sjia) Polyarticular Juvenile Idiopathic Arthritis (pjia) Please
More informationInfusion Checklist for OCREVUS in relapsing or primary progressive forms of multiple sclerosis
Infusion Checklist for OCREVUS in relapsing or primary progressive forms of multiple sclerosis 1 PREINFUSION COUNSELING Provide medication guide and review with your patient Inform patients about the signs
More informationDosing and Administration Guide
Dosing and Administration Guide NULOJIX (belatacept) is available as 250 mg lyophilized powder for injection, for intravenous use. Indication r NULOJIX (in combination with basiliximab induction, mycophenolate
More informationGAZYVA for Previously Untreated Follicular Lymphoma
NOW APPROVED GAZYVA for Previously Untreated Follicular Lymphoma Studied head-to-head vs rituximab * in stage II bulky, III, and IV patients 1 * GAZYVA and rituximab were each combined with bendamustine,
More informationBLINCYTO (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BLINCYTO safely and effectively. See full prescribing information for BLINCYTO. BLINCYTO (blinatumomab)
More informationNCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy
Brentuximab INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): Following autologous stem cell
More informationReimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.
Reimbursement Guide Hospital Outpatient Information provided in this resource is for informational purposes only and does not guarantee that codes will be appropriate or that coverage and reimbursement
More informationAUSTRALIAN PRODUCT INFORMATION Gazyva (obinutuzumab)
AUSTRALIAN PRODUCT INFORMATION Gazyva (obinutuzumab) WARNING Progressive Multifocal Leucoencephalopathy Progressive Multifocal Leukoencephalopathy (PML) including fatal PML can occur in patients receiving
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Arzerra 100 mg concentrate for solution for infusion Arzerra 1000 mg concentrate for solution for infusion 2. QUALITATIVE AND
More informationHERCEPTIN (trastuzumab) for injection, for intravenous use Initial U.S. Approval: 1998
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information for Herceptin. HERCEPTIN (trastuzumab)
More informationNCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy
INDICATIONS FOR USE: INDICATION Brentuximab Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): Following autologous stem cell transplant (ASCT) or Following at least two
More informationReimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.
Reimbursement Guide Hospital Outpatient Information provided in this resource is for informational purposes only and does not guarantee that codes will be appropriate or that coverage and reimbursement
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use North American Coral Snake Antivenin (Equine) safely and effectively. See full prescribing information
More informationOCREVUS TM (ocrelizumab) injection, for intravenous use Initial U.S. Approval: 2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OCREVUS safely and effectively. See full prescribing information for OCREVUS. OCREVUS TM (ocrelizumab)
More informationULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician
BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group
More informationGet the facts about WG, MPA, and Rituxan.
First approved treatment for adults with Wegener s granulomatosis (WG) and microscopic polyangiitis (MPA) Get the facts about WG, MPA, and Rituxan. {Brenda, living with Wegener s granulomatosis} INDICATION
More information*Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GIAPREZA TM safely and effectively. See full prescribing information for GIAPREZA. GIAPREZA (angiotensin
More informationAdministration Tear Pad
GPA & MPA Rituxan for GPA and MPA Administration Tear Pad RITUXAN, IN COMBINATION WITH GLUCOCORTICOIDS, IS THE ONLY FDA-APPROVED INDUCTION THERAPY FOR GRANULOMATOSIS WITH POLYANGIITIS (GPA) AND MICROSCOPIC
More informationRasburicase 1.5 mg/ml powder and solvent for concentrate for solution for infusion. FASTURTEC
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory This package insert is continually updated. Please read carefully before using a new pack. Rasburicase 1.5 mg/ml powder
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationO-CHOP with Obinutuzumab maintenance
O-CHOP with Obinutuzumab maintenance Indication Adult patients with untreated advanced follicular lymphoma with Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 or above. (NICE TA513)
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationBLINCYTO (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BLINCYTO safely and effectively. See full prescribing information for BLINCYTO. BLINCYTO (blinatumomab)
More informationCSL Behring LLC Albuminar -25 US Package Insert Albumin (Human) USP, 25% Revised: 01/2008 Page 1
Page 1 CSL Behring Albuminar -25 Albumin (Human) USP, 25% R x only DESCRIPTION Albuminar -25, Albumin (Human) 25%, is a sterile aqueous solution of albumin obtained from large pools of adult human venous
More informationDOSING AND INFUSION GUIDE
DOSING AND INFUSION GUIDE VPRIV has up to 5 years of data from the largest clinical trial program of an ERT for type 1 Gaucher disease (GD1) 1,2 * *Study 044 was a long-term, open-label extension study
More informationPreparation and Administration
Preparation and Administration A guide for healthcare professionals XOLAIR IS INDICATED FOR: Adults and adolescents (aged 12 years) with moderate-to-severe persistent asthma who have a positive skin test
More informationPRODUCT MONOGRAPH. obinutuzumab. 25 mg/ml Concentrate for Solution for Infusion. Professed Standard. Antineoplastic
PRODUCT MONOGRAPH Pr GAZYVA obinutuzumab 25 mg/ml Concentrate for Solution for Infusion Professed Standard Antineoplastic Hoffmann-La Roche Limited 7070 Mississauga Rd. Mississauga, Ontario, Canada L5N
More informationAn Important Message for Patients and Healthcare Professionals Who Depend on IMBRUVICA (ibrutinib)
An Important Message for Patients and Healthcare Professionals Who Depend on IMBRUVICA (ibrutinib) IMBRUVICA (ibrutinib) is a meaningful and important treatment option for patients with chronic lymphocytic
More informationBC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN)
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code: Tumour Group: Contact Physician: UBRAJTTW Breast Dr. Angela Chan ELIGIBILITY:
More informationOCREVUS (ocrelizumab) Injection, for Intravenous Use
OCREVUS (ocrelizumab) Injection, for Intravenous Use Heidi Crayton, MD Medical Director Multiple Sclerosis Center of Greater Washington Vienna, VA OCR/071916/0181(1) Disclaimer This program is presented
More informationR-Gemcitabine (1000mg/m 2 ) Oxaliplatin Therapy i - 14 day
R-Gemcitabine (1000mg/m 2 ) Oxaliplatin i - 14 day INDICATIONS FOR USE: Regimen Code INDICATION ICD10 Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationACTEMRA SC formulation is not intended for intravenous administration.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. ACTEMRA (tocilizumab)
More informationPRODUCT PROFILE. Clinical evidence for formulary and pathway considerations
PRODUCT PROFILE Clinical evidence for formulary and pathway considerations INDICATION EMPLICITI TM (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients
More informationACTEMRA (tocilizumab) injection, for intravenous use injection, for subcutaneous use Initial U.S. Approval: 2010
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ACTEMRA safely and effectively. See full prescribing information for ACTEMRA. ACTEMRA (tocilizumab)
More information(212) (347)
EMBARGOED FOR MONDAY, JUNE 21, 2010: 3:00 P.M. EST For immediate release: June 21, 2010 Media Contact: Curtis Allen (212) 733-2096 (347) 443-5252 Investors Contact: Suzanne Harnett (212) 733-8009 Pfizer
More informationMedication Policy Manual. Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru196 Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010 Committee Approval Date: January
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION CONTRAINDICATIONS. None.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. ONTAK (denileukin diftitox) Injection
More informationDOSING FLEXIBILITY OF REVLIMID
REVLIMID Dose Adjustments for Thrombocytopenia DISCOVER THE DOSING FLEXIBILITY OF REVLIMID FOR PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) REVLIMID (lenalidomide) is indicated for the treatment of patients
More informationDOSING FLEXIBILITY OF REVLIMID
REVLIMID Dose Adjustments for Renal Impairment DISCOVER THE DOSING FLEXIBILITY OF REVLIMID FOR PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) REVLIMID (lenalidomide) is indicated for the treatment of patients
More informationFludarabine-Cyclophosphamide plus Rituximab (FC-R) for Chronic Lymphocytic Leukaemia
DRUG ADMINISTRATION SCHEDULE First Cycle Only: Day Drug Dose Route Diluent Rate 1 Paracetamol 1gram Oral 1 Hydrocortisone 100mg IV bolus 1 Chlorphenamine 10mg IV bolus 1 Rituximab 375mg/m 2 IV infusion
More informationDOSING & ADMINISTRATION GUIDE
DOSING & ADMINISTRATION GUIDE EXONDYS51.com INDICATION 1 EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is
More informationPRODUCT DISTRIBUTION GUIDE SELECT IMPORTANT SAFETY INFORMATION INDICATION. Infusion-Related Reactions
PRODUCT DISTRIBUTION GUIDE INDICATION LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing
More informationHELPING YOU AND YOUR PATIENTS TALK OPENLY ABOUT MODERATELY TO SEVERELY ACTIVE RA
SIMPONI ARIA (golimumab) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with MTX, active psoriatic arthritis, and active ankylosing
More informationPACKAGE INSERT USP ANTIBIOTIC
Pr AMPICILLIN for Injection USP ANTIBIOTIC ACTIONS AND CLINICAL PHARMACOLOGY Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gramnegative aerobic and anaerobic bacteria.
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZINPLAVA safely and effectively. See full prescribing information for ZINPLAVA. ZINPLAVA (bezlotoxumab)
More informationTaiwan PI for Velcade. (Followed as USPI version Jun 2017; Local version 1701)
Taiwan PI for Velcade (Followed as USPI version Jun 2017; Local version 1701) 1 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Multiple Myeloma Velcade (bortezomib) in combination with other
More informationACTEMRA IV Dosing & Administration Pocket Guide
IMPORTANT SAFETY INFORMATION BOXED WARNING Serious Infections Serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, and other opportunistic
More informationA study population in need of additional treatment options 1,2. The following serious adverse events (AEs) are discussed in greater detail below:
For chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab EXPAND YOUR OPTIONS A study population in need of additional treatment options 1,2 5 median prior therapies 59% 93% 100%
More informationSAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)
SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) Please see Important Safety Information on pages 14 and 15 and accompanying full Prescribing Information. YONDELIS (trabectedin) STUDY DESIGN INDICATION
More information